Clevergene Biocorp Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.27 M
- Company Age 11 Year, 8 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth 39.07%
- Profit Growth -349.24%
- Ebitda -28.98%
- Net Worth -31.65%
- Total Assets 101.67%
About Clevergene Biocorp
Clevergene Biocorp Private Limited (CBPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 04 June 2013 and has a history of 11 years and eight months. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.27 M, as per Ministry of Corporate Affairs (MCA) records.
Tony Jose, Antony Thomas, and Rajasekhara Ravuri serve as directors at the Company.
Company Details
-
Location
Bangaluru, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U73200KA2013PTC069488
-
Company No.
069488
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
04 Jun 2013
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Clevergene Biocorp?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tony Jose
|
Director | 04-Jun-2013 | Current |
|
Rajasekhara Ravuri
|
Director | 02-Jul-2021 | Current |
|
Antony Thomas
|
Director | 16-May-2016 | Current |
Financial Performance of Clevergene Biocorp.
Clevergene Biocorp Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 39.07% increase. The company also saw a substantial fall in profitability, with a 349.24% decrease in profit. The company's net worth observed a substantial decline by a decrease of 31.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Clevergene Biocorp?
In 2021, Clevergene Biocorp had a public holding of 26.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Precision Health Innovations Private LimitedTony Jose and Rajasekhara Ravuri are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Clevergene Biocorp?
Clevergene Biocorp has a workforce of 2 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Clevergene Biocorp, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Clevergene Biocorp's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
